The Patent Finder

Terms ending in 2035

Sandoz AG

Every in-force patent on Sandoz AG's record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,598,718Quantification of Misfolded TNFR2:FC
In force
 · Medium confidence
Sandoz AGIn forceMedium confidence
US 10,865,416Recombinant Host Cell Engineered to Overexpress Helper Proteins
In force
 · High confidence
Boehringer Ingelheim RCV GmbH & Co. KG, Lonza Ltd., Validogen GmbH and Sandoz AGIn forceHigh confidence
US 10,127,839Apparatus For Simulating The Function Of Human Stomach And/Or Human Intestine
Grace period ended Nov 13, 2026 · lapse expected
 · Low confidence
Sandoz AGGrace period ended Nov 13, 2026
lapse expected
Low confidence
US 10,189,860Novel Hydrates Of Dolutegravir Sodium
In force
 · High confidence
Lek Pharmaceuticals D.D.In forceHigh confidence
US 10,590,427Recombinant Host Cell for Expressing Proteins of Interest
In force
 · High confidence
Validogen GmbHIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Sandoz AG.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited